Press Resease

Antiviral Drugs Treatment Market by Drug Class (DNA polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), by Type (Branded, and Generic), and Application (HIV, Hepatitis, Herpes, Influenza, and Others) – Global Industry Perspective Comprehensive Analysis and Forecast, 2020-2026

Published Date: 23-Mar-2020 Category: Healthcare Report Format : PDF Pages: 134 Report Code: ZMR-5329 Status : Published

Global demand for Antiviral Drugs Treatment market was valued at approximately USD 56.2 billion in 2019, and is expected to generate revenue of around USD 65.90 billion by end of 2026, growing at a CAGR of around 2.3% between 2019 and 2026.

Description

The report covers forecast and analysis for the Antiviral Drugs Treatment market on a global and regional level. The study provides historic data from 2016 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Billion). The study includes drivers and restraints for the Antiviral Drugs Treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Antiviral Drugs Treatment market on a global level. In order to give the users of this report a comprehensive view on the Antiviral Drugs Treatment market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Drug Class, Type, Application, and regional segments are benchmarked based on their market size, growth rate and general attractiveness.

Viral infections have caused millions of human casualties worldwide across human history, prompting the production of antiviral drugs in urgent need. A new period of antiviral drug production began in June 1963, when the first antiviral medication, idoxuridine, was approved. Antiviral drugs pertain to the class of medicines that have been used to treat viral infections including HIV, measles, hepatitis, and influenza. In general such medications are distributed in the form of vaccines. Moreover, most of these medications are used for common viral infections, while some (full-spectrum antiviral drugs) are effective against a large range of viruses.

Global Antiviral Drugs Treatment Market

The study provides a decisive view on the Antiviral Drugs Treatment market by segmenting the market based on Drug Class, Type, Application, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2026. Based on Drug Class, the market is segmented into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others.

Based on Type, the market is segmented into Branded, and Generic. Based on Application, the market is segmented into HIV, Hepatitis, Herpes, Influenza, and Others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Geographically speaking, North America dominated the Antiviral Drugs Treatment market with a share of about 37.22% in 2019. The key players’ presence in the region, convenience of refined healthcare infrastructure, and cumulative awareness of viral diseases has led to increased demand for Antiviral drugs in North America region.

Growing occurrence of viral infections such as HIV, hepatitis, respiratory syncytial virus (RSV), and influenza is projected to boost the demand for antiviral drugs. Hepatitis B, for example, has caused about 987,000 deaths in 2017 according to data released by the WHO. In addition, in 2017 about 287 million patients were reported to have been infected with hepatitis B virus (HBV) infection. This is expected to drive the demand for efficient treatment solutions such as antiviral drugs.

Key players within global Antiviral Drugs Treatment market include Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Bristol-Myers Squibb Company; Cipla Inc.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd. & Co., Inc and others.

The report segments global Antiviral Drugs Treatment market as follows:

Global Antiviral Drugs Treatment Market: Drug Class Segment Analysis

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

Global Antiviral Drugs Treatment Market: Type Segment Analysis

  • Branded
  • Generic

Global Antiviral Drugs Treatment Market: Application Segment Analysis

  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others

Global Antiviral Drugs Treatment Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Antiviral Drugs Treatment Market, 2016 - 2026, (USD Billion)
    • 2.2. Antiviral Drugs Treatment Market: Snapshot
  • Chapter 3. Global Antiviral Drugs Treatment Market – Industry Analysis
    • 3.1. Antiviral Drugs Treatment Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of viral infections
      • 3.2.2. Rise in R&D activities and development of newer & advanced formulations
    • 3.3. Restraints
      • 3.3.1. Increasing preventive measures and awareness about the availability of vaccines for viral infections
    • 3.4. Opportunity
      • 3.4.1. Growth opportunities in the emerging economies
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by Drug Class segment
      • 3.6.2. Market attractiveness analysis by Type
      • 3.6.3. Market attractiveness analysis by Application segment
      • 3.6.4. Market attractiveness analysis by regional segment
  • Chapter 4. Global Antiviral Drugs Treatment Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Antiviral Drugs Treatment market: company market share analysis, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Drug Class launches
      • 4.2.3. Agreements, partnerships, cullaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Antiviral Drugs Treatment Market – Drug Class Segment Analysis
    • 5.1. Global Antiviral Drugs Treatment market overview: by Drug Class
      • 5.1.1. Global Antiviral Drugs Treatment market revenue share, by Drug Class, 2019 and 2026
    • 5.2. DNA Pulymerase Inhibitors
    • 5.3. Global Antiviral Drugs Treatment market by DNA Pulymerase Inhibitors, 2016-2026 (USD Billion)
    • 5.4. Reverse Transcriptase Inhibitors
      • 5.4.1. Global Antiviral Drugs Treatment market by Reverse Transcriptase Inhibitors, 2016-2026 (USD Billion)
    • 5.5. Protease Inhibitors
      • 5.5.1. Global Antiviral Drugs Treatment market by Protease Inhibitors, 2016-2026 (USD Billion)
    • 5.6. Neuraminidase Inhibitors
      • 5.6.1. Global Antiviral Drugs Treatment market by Neuraminidase Inhibitors, 2016-2026 (USD Billion)
    • 5.7. Others
      • 5.7.1. Global Antiviral Drugs Treatment market by Others, 2016-2026 (USD Billion)
  • Chapter 6. Global Antiviral Drugs Treatment Market – Type Segment Analysis
    • 6.1. Global Antiviral Drugs Treatment market overview: by Type
      • 6.1.1. Global Antiviral Drugs Treatment market revenue share, by Type , 2019 and 2026
    • 6.2. Growth Factors
      • 6.2.1. Global Antiviral Drugs Treatment market by Growth Factors, 2016-2026 (USD Billion)
    • 6.3. Branded
      • 6.3.1. Global Antiviral Drugs Treatment market by Branded, 2016-2026 (USD Billion)
    • 6.4. Generic
      • 6.4.1. Global Antiviral Drugs Treatment market by Generic, 2016-2026 (USD Billion) 
  • Chapter 7. Global Antiviral Drugs Treatment Market – Application Segment Analysis
    • 7.1. Global Antiviral Drugs Treatment market overview: by Application
      • 7.1.1. Global Antiviral Drugs Treatment market revenue share, by Application, 2019 and 2026
    • 7.2. HIV
      • 7.2.1. Global Antiviral Drugs Treatment market by HIV, 2016-2026 (USD Billion)
    • 7.3. Hepatitis
      • 7.3.1. Global Antiviral Drugs Treatment market by Hepatitis, 2016-2026 (USD Billion)
    • 7.4. Herpes
      • 7.4.1. Global Antiviral Drugs Treatment market by Herpes, 2016-2026 (USD Billion)
    • 7.5. Influenza
      • 7.5.1. Global Antiviral Drugs Treatment market by Influenza, 2016-2026 (USD Billion)
    • 7.6. Others
      • 7.6.1. Global Antiviral Drugs Treatment market by Others, 2016-2026 (USD Billion)
  • Chapter 8. Global Antiviral Drugs Treatment Market - Regional Analysis
    • 8.1. Global Antiviral Drugs Treatment market overview: by region
      • 8.1.1. Global Antiviral Drugs Treatment market revenue share, by region, 2019 and 2026
    • 8.2. North America
      • 8.2.1. North America Antiviral Drugs Treatment market, by country, 2016-2026 (USD Billion)
      • 8.2.2. North America Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
      • 8.2.3. North America Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
      • 8.2.4. North America Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.2.5. The U.S.
        • 8.2.5.1. The U.S. Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.2.5.2. The U.S. Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.2.5.3. The U.S. Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.2.6.2. Rest of North America Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.2.6.3. Rest of North America Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe Antiviral Drugs Treatment market, by country, 2016-2026 (USD Billion)
      • 8.3.2. Europe Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
      • 8.3.3. Europe Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
      • 8.3.4. Europe Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.3.5. U.K.
        • 8.3.5.1. U.K. Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.3.5.2. U.K. Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.3.5.3. U.K. Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.3.6.2. France Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.3.6.3. France Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.3.7. Germany
        • 8.3.7.1. Germany Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.3.7.2. Germany Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.3.7.3. Germany Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of Europe Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.3.8.2. Rest of Europe Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.3.8.3. Rest of Europe Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Antiviral Drugs Treatment market, by country, 2016-2026 (USD Billion)
      • 8.4.2. Asia Pacific Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
      • 8.4.3. Asia Pacific Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
      • 8.4.4. Asia Pacific Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.4.5. China
        • 8.4.5.1. China Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.4.5.2. China Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.4.5.3. China Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.4.6. Japan
        • 8.4.6.1. Japan Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.4.6.2. Japan Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.4.6.3. Japan Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.4.7. India
        • 8.4.7.1. India Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.4.7.2. India Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.4.7.3. India Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.4.8.2. Rest of Asia Pacific Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.4.8.3. Rest of Asia Pacific Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America Antiviral Drugs Treatment market, by country, 2016-2026 (USD Billion)
      • 8.5.2. Latin America Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
      • 8.5.3. Latin America Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
      • 8.5.4. Latin America Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.5.5.2. Brazil Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.5.5.3. Brazil Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
      • 8.5.6. Rest of Latin America
        • 8.5.6.1. Rest of Latin America Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
        • 8.5.6.2. Rest of Latin America Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
        • 8.5.6.3. Rest of Latin America Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
    • 8.6. Middle East & Africa
      • 8.6.1. Middle East & Africa Antiviral Drugs Treatment market, 2016-2026 (USD Billion)
      • 8.6.2. Middle East & Africa Antiviral Drugs Treatment market revenue, by Drug Class, 2016-2026 (USD Billion)
      • 8.6.3. Middle East & Africa Antiviral Drugs Treatment market revenue, by Type , 2016-2026 (USD Billion)
      • 8.6.4. Middle East & Africa Antiviral Drugs Treatment market revenue, by Application, 2016-2026 (USD Billion)
  • Chapter 9. Company Profiles
    • 9.1. Gilead Sciences.
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. F. Hoffmann-La Roche AG
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. GlaxoSmithKline plc.
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. AbbVie
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. Merck & Co., Inc
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Developments
    • 9.6. Johnson & Johnson Services , Inc
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Developments
    • 9.7. Bristul-Myers Squibb Company
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Developments
    • 9.8. Cipla Inc.
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Developments
    • 9.9. Aurobindo Pharma
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Developments
    • 9.10. Dr. Reddy’s Laboratories Ltd.
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product Portfolio
      • 9.10.4. Business Strategy
      • 9.10.5. Recent Developments

Methodology

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social